首页 | 本学科首页   官方微博 | 高级检索  
     

厄贝沙坦联合胺碘酮治疗老年阵发性心房颤动的临床观察
引用本文:曹道俊,慕春言,仝峰,汤日波. 厄贝沙坦联合胺碘酮治疗老年阵发性心房颤动的临床观察[J]. 中南大学学报(医学版), 2008, 33(9): 871-874
作者姓名:曹道俊  慕春言  仝峰  汤日波
作者单位:河南省焦作市第二人民医院心内科,河南,焦作,454001;北京安贞医院心内科,北京,100029
摘    要:目的:评价厄贝沙坦与胺碘酮联合治疗老年阵发性心房颤动(简称房颤)的疗效.方法:将91例年龄≥60岁的阵发性房颤患者随机分为胺碘酮组(Ⅰ组,n=45)和胺碘酮 厄贝沙坦组(Ⅱ组,n=46).治疗后随访18个月.比较两组治疗后3,6,9,12,18个月的窦性心律维持率和治疗前、治疗后6,12,18个月的左房前后径.结果:治疗后3个月,Ⅰ组窦性心律维持率为88.4%,与Ⅱ组(90.9%)比较无统计学差异(P>0.05).治疗后6,9,12,18个月,Ⅰ组窦性维持率分别为72.1%,65.1%,60.5%,55.8%.Ⅱ组分剔为88.6%,86.4%,81.8%,79.5%,两组均有统计学差异(P<0.05).而治疗12个月后,Ⅰ组左心房前后径明显大于Ⅱ组(P<0.05).结论:厄贝沙坦与胺碘酮联合治疗老年阵发性心房颤动维持窦性心律的疗效优于单用胺碘酮,且能抑制左房扩大.

关 键 词:心房颤动  胺碘酮  厄贝沙坦
收稿时间:2008-06-20

Clinical efficacy of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation
CAO Dao-jun,MU Chun-yan,TONG Feng,TANG Ri-bo. Clinical efficacy of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation[J]. Journal of Central South University. Medical sciences, 2008, 33(9): 871-874
Authors:CAO Dao-jun  MU Chun-yan  TONG Feng  TANG Ri-bo
Affiliation:1.Department of Cardiology, Jiaozuo Second Hospital in Henan,Jiaozuo Henan 454001;
2.Department of Cardiology, Anzhen Hospital, Beijing 100029, China
Abstract:OBJECTIVE: To investigate the effect of combination of irbesartan and amiodarone in elderly patients with paroxysmal atrial fibrillation. METHODS: Ninety-one patients with paroxysmal atrial fibrillation were randomly divided into 2 groups: Group I (amiodarone group, n=45) and Group II (amiodarone plus Irbesartan group, n=46).After 18 month follow-up, the maintenance rate of sinus rhythm was measured in the 3rd, 6th, 9th, 12th, and 18th months, and the left atrial diameter (LAD) was measured before the treatment and 6th, 12th, and 18th months after the treatment. RESULTS: There was no difference in the maintenance rate of sinus rhythm between Group I and Group II in the 3rd month. The maintenance rate of sinus rhythm in Group I was 72.1%, 65.1%, 60.5%, and 55.8% in the 6th, 9th, 12th, and 18th months, and the rate in the Group II was 88.6%, 86.4%, 81.8%, and 79.5%. They both had significant difference (P<0.05). At 12 months after the treatment, LAD in Group I was significantly larger than that of Group II (P<0.05). CONCLUSION: The combination of irbesartan and amiodarone is more effective than amiodarone alone for sinus rhythm maintenance, and may restrain the enlargement of the left atrium.
Keywords:atrial fibrillation  irbesartan  amiodarone
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《中南大学学报(医学版)》浏览原始摘要信息
点击此处可从《中南大学学报(医学版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号